SAT0241 Observational Study of Seasonal Monthly Infusions of Iloprost –Experience from A Regional Centre in UK. (15th July 2016)

• Record Type: Journal Article
• Authors: Joshi, P.; Venkatachalam, S.; Sheeran, T.
• Is Part Of: Annals of the rheumatic diseases. Volume 75(2016)Supplement 2
• Page Start: 755
• Page End: 756
• Publication Date: 2016-07-15
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2016-eular.6164
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: Iloprost (Prostacyclin) is effective for resistant Raynaud's phenomenon. We describe our practice of seasonal once monthly infusion which is more cost-effective and flexible than the usual practice of giving iloprost for 3 to 5 days. Objectives: To identify the characteristics, response and tolerance of patients on seasonal monthly infusions of Iloprost from a regional centre in Cannock, United Kingdom. Methods: Retrospective data analysis of patients having monthly iloprost infusions before and during winter for 3–4 months a year (November to February) for resistant Raynaud's phenomenon in 2013 and 2014. Results: There were 72 patients; 57 females and 15 males (F/M =3.8/1), with a mean age of 50.2 (±15.1) years at the start of the iloprost infusion. Underlying diagnosis: Sixty-four patients (88.9%) received calcium channel blockers like nifedipine prior to iloprost and 2 of them also had sildenafil. Thirteen (18.1%) patients had iloprost for 3 to 5 days before switching to seasonal monthly treatment; 8 of them had a digital ulcer or gangrene at presentation. Average follow up was 3.4 (± 2.3) years and mean number of infusions/patient/year was 3.28 ± 0.98.Iloprost improved Raynaud's symptoms in winter in all the patients and was well tolerated by most. Dose adjustment of the iloprost was necessary in 6 (8.3%) patients while 5 (6.9%) of them discontinued due to intolerance. Conclusions: Monthly seasonal iloprost during winter is effective and well tolerated in patients with resistant Raynaud's phenomenon. It is also less expensive than longer courses of iloprost. Disclosure of Interest: None declared